

## REMARKS

Applicants appreciate the Examiner's thorough examination of the subject application. Applicants request reconsideration of the subject application based on the remarks which follow.

As an initial matter, Applicants appreciate the courtesy extended by the Examiner in conducting a telephone interview on February 19, 2008. The rejoinder of Group II of the restriction requirement and the IDS submissions which were not considered were discussed.

Copies of EP 0 089 089 and Purohit, et al., which were submitted in the IDS accompanying the 371 application package, are enclosed herewith for consideration by the Examiner. Applicants provide a new 1449 form listing the two documents and request that the Examiner consider the documents and initial the 1449.

Claims 1-5 and 8-10 are pending in the application. Claims 6 and 7 have been cancelled and claims 1, 3, and 8 have been amended. Cancellation of subject matter from the application by this or a previous amendment was done without prejudice or disclaimer of Applicants right to pursue the cancelled subject matter in one or more continuation or divisional applications. No new matter has been introduced by the instant amendments.

Claim 8 stands rejected under 35 U.S.C. §112, first paragraph, allegedly because the specification, while being enabling for the treatment or prevention of acne, seborrhea, androgenic alopecia, hirsutism, breast cancer, and the treatment of Alzheimer's disease, does not reasonably provide enablement for the prophylaxis of all cancers or Alzheimer's disease.

Claim 8, as amended, provides a method of treatment of disorders mediated by the action of steroid sulfatase which treatment comprises administering to a subject in need of such treatment an effective amount of a compound of claim 1, wherein the disorder is selected from the group consisting of acne, seborrhea, androgenic alopecia, hirsutism, breast cancer, and Alzheimer's disease.

Thus, the rejection of claim 8 appears to be moot in view of the instant amendments.

Claim 6 has been cancelled by the instant response, thus the rejections and/or objections set forth in paragraph 7 on page 5 of the Office Action are rendered moot.

Claims 1 and 5-10 stand rejected under 35 U.S.C. §2, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 has been amended to delete the language "e.g., CF<sub>3</sub>". Thus, claim 1 is fully compliant with the requirements of §112 including the clarity requirements of §112, second paragraph.

Claim 3 has been amended to include a period at the end of the claim.

Early consideration of the application is earnestly solicited.

If for any reason a fee is required, a fee paid is inadequate or credit is owed for any excess fee paid, the Patent Office is hereby authorized and requested to charge Deposit Account No. **50-4409**.

If the Examiner believes that a telephone conference would be of value, she is requested to call the undersigned counsel at the number listed below.


Novartis Institutes for BioMedical Research, Inc.  
400 Technology Square  
Cambridge, MA 02139

(617) 871-3105

Date:

19 Feb 2008

Respectfully submitted,

  
\_\_\_\_\_  
John Alexander  
Attorney for Applicant  
Reg. No. 48,399